Tiny trial tests Dual-Radiation attack on returning prostate cancer

NCT ID NCT05230251

Completed Disease control Sponsor: Glenn Bauman Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This early study tested whether adding a radioactive drug (177Lu-PSMA) to standard brachytherapy is safe and feasible for men whose prostate cancer returned after initial radiation. Only 3 men took part. The goal was to see if the combination could control cancer both in the prostate and elsewhere in the body. Because it was so small, the results are very preliminary.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: 177Lu-PNT2002 (a radioactive drug that targets prostate cancer cells)
What this could lead to: If it works, this combination could offer a new way to treat prostate cancer that has come back after initial radiation, potentially targeting cancer both inside and outside the prostate.
What could go wrong: This was a very small, early-phase study with only 3 participants, so results may not apply to most patients. The treatment also carries risks from radiation exposure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate adenocarcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER

Contacts and locations

Locations

London Health Sciences Centre

London, Ontario, N6A5W9, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.